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Association of Reduced Type IX Collagen Gene Expression in
Human Osteoarthritic Chondrocytes With Epigenetic Silencing
by DNA Hypermethylation
Kei Imagawa,1 Marı´a C. de Andre´s,2 Ko Hashimoto,3 Eiji Itoi,4 Miguel Otero,5
Helmtrud I. Roach,† Mary B. Goldring,5 and Richard O. C. Oreffo2
Objective. To investigate whether the changes in
collagen gene expression in osteoarthritic (OA) human
chondrocytes are associated with changes in the DNA
methylation status in the COL2A1 enhancer and
COL9A1 promoter.
Methods. Expression levels were determined us-
ing quantitative reverse transcription–polymerase chain
reaction, and the percentage of DNA methylation was
quantified by pyrosequencing. The effect of CpG methyl-
ation on COL9A1 promoter activity was determined
using a CpG-free vector; cotransfections with expression
vectors encoding SOX9, hypoxia-inducible factor 1
(HIF-1), and HIF-2 were carried out to analyze
COL9A1 promoter activities in response to changes in
the methylation status. Chromatin immunoprecipita-
tion assays were carried out to validate SOX9 binding to
the COL9A1 promoter and the influence of DNA methyl-
ation.
Results. Although COL2A1 messenger RNA
(mRNA) levels in OA chondrocytes were 19-fold higher
than those in the controls, all of the CpG sites in the
COL2A1 enhancer were totally demethylated in both
samples. The levels of COL9A1 mRNA in OA chondro-
cytes were 6,000-fold lower than those in controls; 6
CpG sites of the COL9A1 promoter were significantly
hypermethylated in OA patients as compared with con-
trols. Treatment with 5-azadeoxycitidine enhanced
COL9A1 gene expression and prevented culture-induced
hypermethylation. In vitro methylation decreased
COL9A1 promoter activity. Mutations in the 5 CpG sites
proximal to the transcription start site decreased
COL9A1 promoter activity. Cotransfection with SOX9
enhanced COL9A1 promoter activity; CpG methylation
attenuated SOX9 binding to the COL9A1 promoter.
Conclusion. This first demonstration that hyper-
methylation is associated with down-regulation of
COL9A1 expression in OA cartilage highlights the piv-
otal role of epigenetics in OA, involving not only hypo-
methylation, but also hypermethylation, with important
therapeutic implications for OA treatment.
Collagen accounts for two-thirds of the dry
weight of adult articular cartilage and confers upon the
tissue the capacity to withstand tensile and shear forces.
Within articular cartilage, type II collagen is the domi-
nant collagen, accounting for more than 90% of the total
collagen. The material strength of articular cartilage is
dependent on the extensive cross-linking of the collagen
and the zonal differences in fibrillar architecture, which
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depend on tissue depth (1). Collagen gene mutations
account for a family of spondyloepiphyseal dysplasias,
which are associated in most cases with early-onset
osteoarthritis (OA) (2).
Type IX collagen is a fibril-associated collagen
with interrupted triple helix (FACIT) that is proposed to
stabilize the fibrillar and proteoglycan networks via
lateral association with type II and type XI collagen (3),
although only 1–5% of the total collagen of mature
cartilage consist of this type of collagen. In contrast,
mice that lack Col9a1 develop normally but display
OA-like cartilage degradation in the knee joints of older
animals (4). Furthermore, the deficiency of Col9a1
chains leads to a functional knockout of all polypeptides
of type IX collagen, even though Col9a2 and Col9a3 are
transcribed normally (5). In humans, COL9A1 has been
identified as a susceptibility locus for OA (6–8), where
mutations predispose to OA but do not account for most
cases. These studies indicate that type IX collagen is
important for the formation of a stable collagen network
and for the maintenance of cartilage organization and
integrity. Reduced levels of type IX collagen in the
matrix may render the cartilage more susceptible to
damage by mechanical forces; thus, reduced COL9A1
expression could ultimately contribute to the pathogen-
esis of human OA.
Gene expression is regulated by both epigenetic
and nonepigenetic mechanisms, leading to up-regulation
or down-regulation of genes that are part of the expres-
sion repertoire of a specific somatic cell type. Epigenet-
ics refers to changes in gene expression without changes
in the DNA sequence. The predominant epigenetic
mechanisms are DNA methylation, histone modifica-
tions, and changes in higher-order chromatin structure.
Nonepigenetic gene regulation is short-term, and ex-
pression reverts upon withdrawal of the relevant factors.
In contrast, epigenetic regulation involves long-term
silencing of all genes that are not normally expressed by
a specific cell type. This silencing is important for
genomic stability, and changes in epigenetic status may
be associated with disease (9).
Methylation of genomic DNA represents a sig-
nificant mechanism for regulating tissue-specific gene
expression. We have previously shown that loss of DNA
methylation underlies the aberrant expression of a num-
ber of catabolic genes in OA chondrocytes, including
MMP genes, ADAMTS4, IL1B, and NOS2 (10–14).
Furthermore, the DNA methylation status of the
MMP13 promoter determines the levels of gene tran-
scription and MMP13 messenger RNA (mRNA) in
chondrocytes (15,16). However, it remains unclear
whether there is a role for either hypomethylation or
hypermethylation in the silencing of anabolic genes
associated with OA. Interestingly, a positive correlation
between age and bone morphogenetic protein 7 (BMP7)
methylation status in chondrocytes isolated from normal
articular cartilage was reported (17), while hypermeth-
ylation of several CpG sites of superoxide dismutase 2
(SOD2) was found in OA cartilage, which correlated
with decreased expression of the SOD2 gene (18).
Recent studies have shown the association of changes in
DNA methylation status with the expression of the
OA-associated gene GDF5 (19), and increased DNA
methylation and altered histone modification were ob-
served in a study of the epigenetic status of the SOX9
promoter (20).
Zimmermann and collaborators (21) have previ-
ously observed that the CpG island around the transcrip-
tion start site (TSS) of the COL2A1 promoter was
completely demethylated in human articular chondro-
cytes, mesenchymal stem cells (MSCs), and MSC-
derived chondrocytes independently of COL2A1 gene
expression. Levels of DNA methylation of the CpG sites
in the 309-bp enhancer region, which is required for
COL2A1 transcription (21,22), had not been studied,
however. We therefore examined the CpG methylation
profile of the COL2A1 enhancer region for a potential
functional linkage to COL2A1 gene expression.
It is known that the COL9A1 promoter region
from 846 bp to the TSS is important for its transcrip-
tional regulation (23), and although there are 8 CpG
sites in this promoter sequence, the effect of methylation
on COL9A1 transcription remains undetermined. In
addition, the COL9A1 promoter is known to have 5
SOX9-binding sites and 1 hypoxia inducible factor 1
(HIF-1)/HIF-2–binding site. SOX9, a transcription
factor that is pivotal in chondrogenic differentiation,
activates COL9A1 gene expression (23). However, the
role of CpG methylation in COL9A1 transactivation by
SOX9 remains unknown.
HIF-1 acts as a survival factor by enhancing
extracellular matrix (ECM) synthesis (24) and inhibiting
apoptosis (25). In contrast, HIF-2 is a catabolic regu-
lator of OA cartilage destruction (26), and the binding
and transactivation of MMP13 by HIF-2 were shown to
be inhibited by methylation of a specific CpG site in the
proximal promoter (15).
The aim of the present study was to investigate
whether the changes in collagen gene expression in
human OA chondrocytes are associated with changes in
the DNA methylation levels in the COL2A1 enhancer
and COL9A1 promoter.
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MATERIALS AND METHODS
Chondrocyte isolation. Human chondrocytes were iso-
lated from the articular cartilage of femoral heads obtained at
the time of surgery for total hip replacement (12 OA patients
[4 men and 8 women], with a mean  SD age of 72.4  7.9
years) or for femoral neck fracture (10 control subjects [2 men
and 8 women], with a mean  SD age of 79.2  5.8 years), as
previously described (27). Permission of the Local Ethics
Committee and consent of the patients were obtained prior to
this study.
Chondrocyte culture. Only “non-OA chondrocytes”
from the deep zone of tissues obtained from the patients with
femoral neck fracture were used (27). Isolated chondrocytes
were divided into 3 groups: noncultured (preculture), cultured
without treatment (control culture), and cultured using 2 M
5-azadeoxycytidine (5-aza-dC). Prior to treatment, chondro-
cytes were cultured for 48 hours at 37°C at a density of 2–4 
105 cells in Dulbecco’s modified Eagle’s medium (DMEM)/
F-12 medium supplemented with 5% fetal calf serum, 1%
insulin–transferrin–selenium, 100 units/ml of penicillin, 100
g/ml of streptomycin, and 100 g/ml of ascorbic acid in an
atmosphere of 5% CO2.
For samples cultured with 5-aza-dC, the histone
deacetylase inhibitor trichostatin A (TSA; 300 nM) was added
at the first treatment to facilitate access of 5-aza-dC, a cytidine
analog that impedes the proper activity of DNA methyltrans-
ferase 1 (28). The media were changed twice weekly, and the
primary cultures were maintained for 5 weeks until the samples
reached confluence.
DNA and RNA extraction. Total RNA and genomic
DNA were extracted simultaneously from each sample with an
AllPrep DNA/RNA Mini kit (Qiagen) according to the man-
ufacturer’s instructions. RNA was immediately reverse-
transcribed with avian myeloblastosis virus reverse transcrip-
tase and both oligo(dT)15 and random primers (29).
Quantitative reverse transcription–polymerase chain
reaction (qRT-PCR) analysis. Relative quantification of gene
expression in total RNA extracts was performed with an ABI
Prism 7500 detection system (Applied Biosystems). Reactions
were performed in triplicate, with GAPDH as the internal
control. Messenger RNA expression was quantified according
to the 2Ct method, as previously described (9). Primer
information is available upon request.
DNA methylation analysis by bisulfite pyrosequencing.
Bisulfite treatment of the genomic DNA of each sample was
performed using an EZ DNA Methylation-Gold kit (Zymo
Research) according to the manufacturer’s instructions, as
previously described (14).
The percentage of DNA methylation in the COL2A1
enhancer or the COL9A1 promoter was quantified using a
PyroMark MD system (Qiagen) according to the manufactur-
er’s instructions. Primer information is available upon request
from the corresponding author. Three primer sets were de-
signed for each sequence of the COL2A1 enhancer and
COL9A1 promoter to encompass the CpG sites of interest
(Figure 1).
COL9A1-Luciferase constructs. The human COL9A1
proximal promoter region was PCR amplified from the
genomic DNA isolated from human chondrocytes. The origi-
nal sequences of the primers were derived from descriptions in
the literature (23). The 5 additional sequences of forward and
reverse primers were modified to contain Spe I (construct 1
[C1]), Bam HI (C2), Hind III (C3), and Nco I sites to facilitate
cloning. The PCR-generated promoter fragments (976 bp)
contained the regions spanning 846 to 130 bp (C1), 565
to 130 bp (C2), and 169 to 130 bp (C3) relative to the
TSS in the human COL9A1 gene sequence. The promoter
regions were cloned into the respective sites of the pCpG-free
luciferase reporter vector constructed as described in the
literature (15,30). After constructing the pCpG-free-Luc-
Figure 1. Features of the 309-bp COL2A1 enhancer element (top) and the COL9A1 promoter region (bottom). HIF-1  hypoxia inducible factor 1.
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COL9A1 vectors (C9–wild-type [C9-WT; C1], C2, and C3),
pCpG-free-Luc-COL9A1-M1, M2, and M3 vectors were also
produced with mutations in the CpG sites (see below). Primer
information is available upon request from the corresponding
author. In all cases, the correct insertion of constructs was
determined by sequencing analysis.
In vitro methylation of plasmid DNA. Methylated
plasmids were generated by incubating 1 g of plasmid DNA
with 4 units/l of the CpG methyltransferase, M.Sss I (New
England BioLabs), according to the manufacturer’s instruc-
tions. Complete methylation was verified by plasmid DNA
bisulfite modification and pyrosequencing using specific primers.
Transient transfection and luciferase assays. Cells of
the immortalized human chondrocyte line C28/I2 (31) were
seeded at a density of 30,000/well, cultured overnight in
DMEM, and transfected with a mixture of 500 ng of luciferase
reporter vector and 1 ng of pRL-SV40 vector, using TurboFect
in vitro transfection reagent (Fermentas) and FuGene HD
(Promega) according to manufacturers’ recommendations.
Transfected C28/I2 cells were cultured for 24–48 hours prior
to harvest. Cell lysates were assayed for firefly and Renilla
luciferase activity using a Dual-Luciferase Reporter Assay
system (Promega) on a Varioskan Flash reader (Thermo).
Firefly luciferase activity for each transfection was normalized
against Renilla luciferase activity. For the cotransfection as-
says, 500 ng of SOX9-pcDNA vector (32) and 500 ng of the
HA-HIF-1-pcDNA3 vector (Addgene plasmid 18949) or the
HA-HIF-2-pcDNA3 vector (Addgene plasmid 18950) (33)
were used. The pcDNA3 vector (Invitrogen) served as a
negative control.
Chromatin immunoprecipitation (ChIP) assay. A
ChIP-IT Express Enzymatic kit (Active-Motif) was used to
perform ChIP assays according to the manufacturer’s instruc-
tions, as described elsewhere (15). Briefly, C28/I2 cells were
cotransfected with unmethylated or methylated pCpG-free-
Luc-COL9A1 vector (846 to 130 bp) and the expression
vector encoding SOX9 using FuGene HD (Promega). At 48
hours following transfection, precleared chromatin was stored
as assay input or was incubated overnight at 4°C with 5 g of
rabbit anti-SOX9 antibody (Abcam) or normal rabbit IgG
(Cell Signaling Technologies). After reverse cross-linking and
purification, the final DNA preparations were subjected to
qPCR analysis using 5 l of the eluted DNA. For analysis, the
Ct of each sample was normalized to the Ct of the input
sample. Specific primers for each binding site were designed
(primer information is available upon request from the corre-
sponding author).
Statistical analysis.Expression and percentage methyl-
ation data were analyzed using Wilcoxon’s signed rank test.
The data for COL9A1 luciferase reporter assay were analyzed
using analysis of variance with a post hoc t-test to check the
differences between two groups. P values less than 0.05 were
considered significant.
RESULTS
Features of the COL2A1 enhancer and the
COL9A1 promoter regions. The structures of the 309-bp
enhancer region of COL2A1 and the promoter region of
COL9A1 are shown in Figure 1. The 309-bp enhancer
region of COL2A1 has 21 CpG sites, and the COL9A1
promoter has 8 CpG sites. The 2610-bp CpG site in
the COL2A1 enhancer and 8-bp CpG site in the
COL9A1 promoter were not analyzed. The COL9A1
promoter construct contains 1 HIF-1/HIF-2 binding
site and 5 SOX9 binding sites.
No relationship between increased COL2A1
mRNA levels in OA chondrocytes and DNA methylation
changes in the 309-bp COL2A1 enhancer. Chondrocytes
were isolated from cartilage, and extracts of total RNA
were immediately prepared for qRT-PCR analysis.
COL2A1 mRNA levels in chondrocytes derived from
OA patients were 9-fold higher than those in control
chondrocytes (Figure 2A).
The percentage of DNA methylated CpG sites in
the 309-bp enhancer of COL2A1 was quantified using
pyrosequencing to determine whether the increase in
COL2A1 expression in OA chondrocytes was associated
with epigenetic unsilencing by DNA demethylation (Fig-
ure 2B). The 309-bp sequence contains 21 CpG sites; 3
primer pairs were designed to cover the 21 CpG sites in
the COL2A1 enhancer (Figure 1). All CpG sites ana-
lyzed in the 309-bp COL2A1 enhancer were almost
completely demethylated in both femoral neck fracture
and OA samples.
Association between the loss of COL9A1 gene
expression in OA chondrocytes and hypermethylation of
CpG sites in the COL9A1 promoter. High levels of
COL9A1 expression were observed in control samples,
although considerable patient-to-patient variation was
noted. Interestingly, COL9A1 mRNA levels in OA chon-
drocytes were significantly different and were determined
to be 6,200-fold lower than those in chondrocytes from
patients with femoral neck fracture (Figure 2C). Potential
differences between expression profiles may exist when
comparing results from isolated cells with those obtained
from RNA isolated directly from articular cartilage.
To determine whether the loss of COL9A1 ex-
pression in OA cartilage was associated with DNA
hypermethylation, DNA methylation levels were quan-
tified by bisulfite pyrosequencing. The COL9A1 pro-
moter contains 8 CpG sites in the proximal promoter,
and 3 primer pairs were designed to cover the CpG sites
located at 632, 614, and 599 bp, 400 and 382
bp, and 95 and 49 bp. At the CpG sites closest to the
TSS, negligible DNA methylation was observed (4%)
in femoral neck fracture samples, but it was 8% to 14%
higher in OA samples. At the 400-bp and 382-bp
sites, the overall percentage methylation was higher than
at the CpG closest to the TSS, at 5% and 20%, respec-
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tively, in femoral neck fracture samples and 13% and
24%, respectively, in OA samples. Significant differ-
ences in the percentage methylation were observed
between control and OA patient samples at 400 bp,
although not at 382 bp (Figure 2D). In contrast,
enhanced methylation at CpG sites 632, 614, and
599 bp were observed with, on average, 	40% meth-
ylated sites in control samples and 	60% in OA chon-
drocytes. A significant reciprocal trend between the
percentage of DNA methylation and mRNA expression
was observed, and the magnitude of hypermethylation in
OA samples was found to be greatest between CpG sites
632 bp and 599 bp (Figure 2D).
Association between loss of COL9A1 expression
in culture and hypermethylation. Since monolayer cul-
ture is known to affect the gene expression profile of
chondrocytes (34), COL9A1 mRNA levels were ana-
lyzed in preculture chondrocytes and compared with
chondrocytes that had been cultured for 5 weeks (Figure
3A). Chondrocytes were obtained from patients with
femoral neck fracture. The culture of chondrocytes
proved detrimental to COL9A1 expression, with signifi-
cant loss of expression. Analysis of the percentage of
DNA methylation of the COL9A1 promoter demon-
strated that the significant loss of COL9A1 expression as
a consequence of culture was associated with hyper-
methylation (Figure 3B).
Enhanced COL9A1 expression and prevention of
culture-induced hypermethylation following 5-aza-dC
treatment. We examined whether culture-induced hy-
permethylation of CpG sites in the COL9A1 promoter
could be ameliorated by 5 weeks of treatment with
5-aza-dC (trichostatin A was added once to facilitate
access of 5-aza-dC). COL9A1 mRNA levels in chondro-
cytes cultured with 5-aza-dC were 	7-fold higher than
those in control culture chondrocytes (Figure 3C). Sig-
nificantly, the percentage methylation of the COL9A1
promoter in these chondrocyte cultures was maintained
Figure 2. Correlation between hypermethylation at specific COL9A1 proximal promoter CpG sites in chondrocytes from patients with osteoarthritis
(OA) and reduced levels of gene expression in OA disease. A and C, Relative expression of mRNA for COL2A1 (A) or COL9A1 (C) in non-
cultured primary chondrocytes from 10 patients with femoral neck fracture (NOF; controls) and 12 patients with OA, as determined by quanti-
tative reverse transcription–polymerase chain reaction analysis and normalized against GAPDH. B and D, Percentage DNA methylation of the
indicated CpG sites on the COL2A1 (B) and COL9A1 (D) proximal promoters in chondrocytes from the 10 femoral neck fracture patients and 12
OA patients, as determined by bisulfite pyrosequencing analysis of the same samples. Values are the mean  SD of triplicate (A and C) or duplicate
(B and D) determinations for each sample. Samples tested in B and D are the same as those in A and C, respectively.   P  0.05 for OA versus
controls.
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at levels comparable to those in preculture chondrocytes
(Figure 3D).
Methylation-induced decrease in COL9A1 pro-
moter activity in vitro. To determine the effect of
methylation on COL9A1 promoter activity, we used a
luciferase reporter assay. C28/I2 chondrocytes were
transfected with the wild-type COL9A1 construct in the
CpG-free vector (C9-WT) or with deletions from the 5
end of constructs C2 (565 to 130 bp) and C3 (169
to130 bp) and pRL-SV40 vector as an internal control
and were then harvested for the luciferase assay. Meth-
ylation treatment significantly decreased the activities of
the 3 constructs (Figure 4A). Interestingly, shorter con-
structs were significantly more active than WT, indicat-
ing that CpG sites closer to the TSS are crucial to
COL9A1 promoter activity.
Association between mutations in the 3 CpG sites
proximal to the TSS and decreased COL9A1 promoter
activity. To determine the critical CpG sites for
COL9A1 promoter activity, we compared the C9-WT
and 3 vectors with mutations at different CpG sites
(Figure 4B). Methylation decreased the COL9A1 pro-
moter activity in cells transfected with C9-WT or with
any of the 3 vectors containing CpG mutations. Signifi-
cantly lower activity was observed in cells transfected
with C9-M3 as compared those transfected with C9-WT
Figure 3. Correlation of culture conditions and CpG demethylation in vitro with decreased and enhanced levels of COL9A1 gene expression in
chondrocytes obtained from 10 patients with femoral neck fracture. A and C, Relative mRNA expression of COL9A1 in preculture chondrocytes
compared with control culture chondrocytes (A) as well as in control culture chondrocytes compared with chondrocytes cultured for 5 weeks in
5-azadeoxycytidine (5-aza-dC [5-aza]; with trichostatin A added once to facilitate access of 5-aza-dC) (C), as determined by quantitative reverse
transcription–polymerase chain reaction analysis. B and D, Percentage DNA methylation of the indicated CpG sites in the COL9A1 promoter in
preculture chondrocytes compared with control culture chondrocytes (B) as well as in control culture chondrocytes compared with chondrocytes
cultured for 5 weeks in 5-aza-dC (D) , as determined by bisulfite pyrosequencing analysis of the same samples. Values are the mean SD of triplicate
(A and C) or duplicate (B and D) determinations for each sample (n  10 preculture samples, n  7 control culture samples, and n  6
5-aza-dC–treated samples).   P  0.05 for preculture or 5-aza-dC–treated samples versus control culture samples.
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in their unmethylated forms, indicating that the 3 CpG
sites proximal to the TSS are key for COL9A1 pro-
moter activity. The ratios of luciferase activities in
unmethylated-to-methylated vectors were 1.9, 1.9, 3.3,
and 1.5 in C9-WT, M1, M2, and M3, respectively, with a
smaller ratio indicating a reduced effect of methylation
on promoter activity.
SOX9-induced enhancement of COL9A1 pro-
moter activity. The sequence of the 5-flanking region of
the human COL9A1 gene from 711 to 13 bp is shown
in Figure 5A. The CpG positions and the 5 putative SOX9-
binding sites (BS1–BS5) in the construct are highlighted.
To determine the effects of the transcription
factors HIF-1, HIF-2 (data not shown), and SOX9 on
COL9A1 promoter activity, the expression vector encod-
ing each transcription factor or the pcDNA3 empty
vector was cotransfected with C9-WT (C1), C9-C2, or
C9-C3. Overexpression of either HIF-1 or HIF-2 had
a negligible effect on the activities of all the constructs
(data not shown). Consistent with previous work (23),
SOX9 overexpression increased the activity of C9-WT
and, especially C9-C2 and C9-C3, constructs that have 5
and 3 CpG sites, respectively, showing an increase in
luciferase activity of 	56-fold and 	8.75-fold, respec-
tively (Figure 5B). Interestingly, CpG methylation sig-
nificantly attenuated this SOX9-mediated promoter ac-
tivation in all constructs (Figure 5B).
Requirement of 5 CpG sites proximal to the TSS
for transactivation of COL9A1 by SOX9. To determine
which CpG sites within the COL9A1 promoter were
critical for SOX9 transactivation, each of the 4 COL9A1
vectors (C9-WT, M1, M2, and M3) was cotransfected
with the pcDNA-SOX9 vector (Figure 5C). Mutation of
the 3 CpG sites in the upstream region (C9-M1) had a
negligible effect on transactivation of the COL9A1 pro-
moter by SOX9. In contrast, the mutations in the 5 CpG
sites close to the TSS resulted in significant loss of
COL9A1 promoter activity. The ratios of SOX9-driven
luciferase reporter activity in unmethylated-to-methylated
vectors were 5.8, 5.6, 6.3, and 2.3 in C9-WT, M1, M2,
and M3, respectively.
CpG methylation–induced attenuation of SOX9
binding to the COL9A1 promoter. In order to analyze
our results in more detail, we investigated whether the
Figure 4. Effect of methylation of CpG sites in the proximal human COL9A1 gene promoter on transcriptional activity. COL9A1 promoter activity
was analyzed using the luciferase (Luc) assay in C28/I2 chondrocytes transfected with either C1 (wild-type [WT]) or deletions from the 5 ends of
constructs C2 and C3 (A) or transfected with specific CpG mutations (M1, M2, and M3) (B), without (Meth) or with (Meth) CpG methylation
treatment. Values are the mean  SD of 3–5 independent experiments, each performed in triplicate.   P  0.05 versus no methylation treatment
or for the indicated comparison, by analysis of variance with post hoc t-test.
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CpG methylation status directly affected SOX9 binding
to the proximal COL9A1 promoter in ChIP assays per-
formed using C28/I2 chondrocytes cotransfected with
unmethylated or methylated WT 846 to 130-bp
COL9A1 promoter constructs and expression vectors
encoding SOX9. COL9A1 promoter binding was ana-
lyzed with specific PCR primers that recognized only the
transiently transfected promoter construct. In addition,
primers were specifically designed to recognize each
putative SOX9-binding site. ChIP assays revealed that
methylation treatment significantly reduced SOX9 bind-
ing to the COL9A1 proximal promoter, specifically to
the putative binding sites BS4 and BS5 (Figure 6). These
observations are consistent with our results showing
Figure 5. Impaired SOX9-driven COL9A1 promoter transactivation in the presence of CpG methylation. A, Sequence of the proximal human
COL9A1 promoter. SOX9 putative binding sites (BS1–BS5), as well as the hypoxia inducible factor 1 (HIF-1) binding site, are underlined.
Positions of CpG sites are indicated (652 bp to 8 bp). B, Different unmethylated (Meth) and methylated (Meth) COL9A1 constructs were
cotransfected with the empty control vector (pcDNA3) or with the SOX9 expression vector. C, Effect of CpG mutation on SOX9 cotransfection.
Constructs and CpG mutations used for transfections are the same as those in Figure 4. Values in B and C are the mean  SD of 3 independent
experiments, each performed in duplicate.   P  0.05 versus SOX9 no methylation treatment in B and versus no methylation treatment in C and
for the indicated comparisons.
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decreased SOX9-driven COL9A1 transactivation after
methylation treatment of the mutant COL9A1 reporter
constructs (Figure 5B).
DISCUSSION
Our current findings indicate that the increased
COL2A1 mRNA levels that we observed in OA chon-
drocytes do not correlate with changes in the methyl-
ation status, either at the promoter or the enhancer
regions. This is contrary to our recent findings on the
NOS2 enhancer (14) and MMP13 promoter (15). It is
possible that in the absence of differential methylation,
the increased expression of COL2A1 observed in OA
chondrocytes could be explained by the regenerative
efforts of the cells to restore the ECM as an anabolic
response within a degradative environment. Further-
more, the widespread expression of COL2A1 in OA
chondrocytes suggests a compensatory response to the
absence of COL9A1. Our findings of increased COL2A1
expression in OA are consistent with those observed by
Ijiri and coworkers (35) and by Aigner and collaborators
(36) in microarray analyses.
Interestingly, Sesselmann and colleagues (37)
reported that DNA methylation of the promoter of
p21WAF1/CIP1 is not responsible for down-regulation
of p21WAF1/CIP1 mRNA in OA chondrocytes. Since
p21WAF1/CIP1 is an inhibitor of proliferation that is
expressed in normal chondrocytes, it was postulated that
down-regulation in OA, which is associated with in-
creased cell division, may have an epigenetic compo-
nent. Similarly, Poschl and colleagues (38) reported that
DNA methylation is not a key component of the down-
regulated expression of aggrecan, another major chon-
drocyte gene. None of these studies could demonstrate
changes in the methylation status of genes related to OA
phenotype.
It is likely that the crucial difference between our
results lies in the promoter structure of the gene. Both
aggrecan and the p21 promoters did not show any
difference in the DNA methylation status in their non-
coding regions, which contain CpG islands that are
absent from the COL9A1 promoter. As shown by the
Human Epigenome Project (39), genes with large num-
bers of CpG islands are, in general, not methylated in
normal cells, irrespective of expression. Treatment with
5-aza-dC provided a useful tool with which to determine
whether decreased methylation caused the activation of
transcription in a specific gene (20). The current obser-
vations demonstrate that the low level of COL9A1
mRNA in OA chondrocytes could be reversed through
Figure 6. Attenuated SOX9 binding to the COL9A1 promoter in the
presence of CpG methylation. Chromatin immunoprecipitation assays
were performed using cell lysates from C28/I2 cells that had been
transfected with an unmethylated (Meth) or a methylated (Meth)
wild-type (846 to130-bp) COL9A1 promoter construct (Input) and
the expression vector encoding SOX9. Binding of transcription factor
to the human COL9A1 promoter was analyzed by quantitative poly-
merase chain reaction using primers specifically bracketing SOX9-
binding sites BS4 and BS5. The results were quantified and are shown
as the percentage input. Values are the mean  SD of 4 experiments
and represent the fold-change versus IgG.   P  0.05.
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inhibition of DNA methylation. Our findings of de-
creased COL9A1 expression in OA are consistent with
recent proteomic (40) and microarray studies (41);
however, other groups failed to observe this significant
decrease in COL9A1 expression on gene profiling of OA
(36,42,43).
To determine the role of DNA methylation on
the COL9A1 promoter, we used a CpG-free vector (30)
within a transfection assay in vitro. Site-directed muta-
tions of the 8 CpG sites within the 976-bp COL9A1
promoter in the construct revealed, for the first time,
that COL9A1 promoter activity is significantly decreased
by CpG methylation in articular chondrocytes. We found
significantly lower promoter activity when we trans-
fected C9-M3, which lacks 3 CpG sites proximal to the
TSS, as compared with C9-WT. Similarly, other investi-
gators (44) have reported that effective gene suppres-
sion is observed only when promoters are methylated in
the preinitiation domain.
Zhang and coworkers (23) reported that the
560 to 357-bp region of the COL9A1 promoter is
important for full COL9A1 promoter activity in the rat
chondrosarcoma cell line. In this current study, mutation
of the 400 and 382-bp CpG sites in C9-M2 did not
alter promoter activity. Thus, it can be assumed that the
promoter activity of the 560 to 357-bp sequence is
regulated by a mechanism other than CpG methylation
within that region. In contrast, our study indicates that 3
CpG sites (95, 49, and 8 bp) in the proximal
promoter are also important for full COL9A1 promoter
activity.
SOX9 is a transcription factor that is essential for
chondrogenesis (45) and indispensable for skeletogen-
esis (46,47). While some reports indicate no changes or
increased expression of SOX9 in early OA disease (48),
OA is generally associated with down-regulation of
SOX9 expression (49). However, the lack of positive
correlation between SOX9 and COL2A1 expression in
adult articular chondrocytes suggests that while SOX9 is
essential for chondrogenesis (45) and normal and OA
cartilage homeostasis, it is not the key regulator of the
COL2A1 promoter activity in human adult articular
chondrocytes (50). Furthermore, Kim et al (20) recently
reported that hip OA is associated with a change in the
epigenetic status of the SOX9 promoter, including in-
creased DNA methylation and altered histone modifica-
tions. The cause–effect relationship between the epige-
netic change in SOX9 promoter and hip OA was not
elucidated, however.
Taking into account the down-regulation of
SOX9 expression during chondrocyte dedifferentiation,
its hypermethylated promoter in OA disease, and its
methylation-dependent control of COL9A1 transcrip-
tion, it is conceivable that the OA environment associ-
ated with decreased SOX9 expression and abnormal
methylation patterns enhance the susceptibility of the
COL9A1 promoter to DNA methylation.
It has been shown that SOX9 enhances COL9A1
promoter activity (23); however, the CpG sites in the
COL9A1 promoter required for transactivation by
SOX9 remain unknown. Consistent with Zhang et al
(23), our results indicate that methylation of the CpG
sites in the COL9A1 promoter attenuated the SOX9-
mediated enhancement. Mutation analysis confirmed
that the 5 CpG sites proximal to the TSS were respon-
sible for the enhancement of COL9A1 promoter activity
by SOX9.
Using promoter mutation constructs it appears
that the regions that are susceptible to methylation may
be the same as those that are responsible for SOX9
binding and transcriptional activation. Interestingly, mu-
tation does not completely abolish the effect of methyl-
ation, which suggests that methylation at multiple sites
throughout the COL9A1 promoter determines tran-
scription. Consistent with Zhang and collaborators, en-
hanced promoter activity was observed after cotransfec-
tion of the C2 construct with SOX9; indeed, direct
mutagenesis of 400 and 382 bp (M2) and/or 95,
49, and 8 bp (M3) showed the most significant
decrease in the promoter activity.
This study is the first to show that in chondro-
cytes, CpG methylation of the COL9A1 proximal pro-
moter specifically impairs SOX9-driven promoter acti-
vation by altering SOX9 binding to DNA and that
transactivation depends mainly on the DNA methylation
status of 2 SOX/sex-determining region Y (SRY) bind-
ing sites (BS4 and BS5).
In contrast, cotransfection experiments carried
out with HIF-1 and HIF-2 showed no significant
changes, indicating that they are not the key transcrip-
tion factors that modulate COL9A1 promoter activity
(data not shown). It is thus likely that other transcription
factors intercalating between HIFs and COL9A1 modu-
late function, and this will require further investigation.
In conclusion, epigenetic changes in OA involve
hypomethylation and the consequent activation of aber-
rant, catabolic genes, as well as hypermethylation lead-
ing to silencing of at least 1 chondrocytic gene that
contains sparse CpG sites at important regulatory do-
mains. This is the first demonstration that hypermethyl-
ation is associated with down-regulation of COL9A1
expression in OA, indicating the pivotal role of epige-
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netics in decreased anabolism in OA. Undoubtedly,
other genes subject to epigenetic regulation remain to be
identified in OA, and while changes in DNA methyl-
ation will not always explain the permanent alteration of
gene expression in OA chondrocytes, our studies suggest
that approaches that incorporate prevention or reversal
of epigenetic changes offer significant therapeutic po-
tential for OA in an increasing patient demographic.
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